Ultragenyx Pharmaceutical Inc.RARENASDAQ
Loading
Operating Expenses Over TimeStrong
Percentile Rank100
3Y CAGR+3.8%
5Y CAGR+13.1%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+3.8%/yr
vs +23.6%/yr prior
5Y CAGR
+13.1%/yr
Recent deceleration
Acceleration
-19.8pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
1.8x
Solid growth
Streak
2 yr
Consecutive growthStrong
PeriodValueYoY Change
2025$1.10B+7.8%
2024$1.02B+6.4%
2023$958.25M-2.6%
2022$983.93M+37.2%
2021$717.13M+20.5%
2020$595.02M+14.7%
2019$518.88M+23.0%
2018$421.72M+27.2%
2017$331.55M+33.6%
2016$248.14M-